Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093028 · ClinicalTrials.gov registry record · Phase 3
Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II
A Phase 3 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 3
- Development phase
- 315
- Enrollment target
NCT00093028 is a Phase 3 study that has completed, run by University of Arkansas. The registered enrollment target is 315 participants.
The verdict
NCT00093028, a Phase 3 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 315 participants
- Enrollment target
Study Summary
The purpose of this study is * to find out the effects of treating patients with two new chemotherapy drugs (bortezomib and Revlimid™), * to study how many patients' myeloma responds to treatment on this study, and how many patients survive after this treatment, * to learn if a patient's genetic makeup before and after treatment can predict which patients will respond to bortezomib and Revlimid™, and to learn more about how the body responds (gene array studies).
Interventions
- DRUG bortezomib
- DRUG CC-5013 (Revlimid™)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093028
The ClinicalTrials.gov registry entry for NCT00093028 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bortezomib is the first listed.
NCT00093028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093028 about?
NCT00093028 is a clinical study titled "Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II". The purpose of this study is * to find out the effects of treating patients with two new chemotherapy drugs (bortezomib and Revlimid™), * to study how many patients' myeloma responds to treatment on this study, and how many patients survive after this treatment, * to learn if a patient's genetic ma...
What is the current status of trial NCT00093028?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 315 participants. The study started on 2004-01. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00093028?
The interventions under investigation include: bortezomib (DRUG), CC-5013 (Revlimid™) (DRUG).
Who is sponsoring clinical trial NCT00093028?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.